SCHEMBL6037518

SCHEMBL6037518

[CH2]c1ccc(-n2c(=O)[nH]c(=O)c3ccccc32)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAT2A P31153 6/20 0.49
L3MBTL1 Q9Y468 2/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
KMT2A Q03164 1/20 0.41
PARP1 P09874 2/20 0.40
CYP1A2 P05177 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ATM Q13315 1/20 0.40
DAO P14920 1/20 0.37
TNKS O95271 1/20 0.36
NTRK1 P04629 1/20 0.36
IGF1R P08069 1/20 0.36
FGFR1 P11362 1/20 0.36
NTRK3 Q16288 1/20 0.36
NTRK2 Q16620 1/20 0.36
LCK P06239 1/20 0.35
PRKACA P17612 1/20 0.35
CSNK2A2 P19784 1/20 0.35
PRKACG P22612 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9836581 0.86 MAT2A (0.61) MAT2AL3MBTL1MEN1LMNAKMT2A
SCHEMBL6037521 0.84 ALDH1A1 (0.50) MAT2ALMNAKMT2APARP1CYP1A2
SCHEMBL18020186 0.79 MAT2A (0.54) MAT2AL3MBTL1MEN1LMNAKMT2A
SCHEMBL18020187 0.72 MAT2A (0.41) MAT2AL3MBTL1MEN1LMNAKMT2A
SCHEMBL12822423 0.72 MAT2A (0.75) MAT2AL3MBTL1MEN1KMT2APARP1
SCHEMBL10999663 0.71 GSR (0.52) MAT2AKMT2ACYP1A2KDM4ELCK
SCHEMBL17501689 0.70 PKM (0.42) MAT2AMEN1LMNAKMT2APARP1
SCHEMBL29654412 0.70 PKM (0.42) MAT2AMEN1LMNAKMT2APARP1
SCHEMBL15206647 0.70 PDE7A (0.57) MAT2AL3MBTL1MEN1KMT2AKDM4E
SCHEMBL10889569 0.70 PDE4A (0.57) MAT2AMEN1KMT2APARP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030018016-A1 Cell adhesion inhibitors BIOGEN IDEC MA, INC. 2003-01-23 US claimed
EP-0805796-B1 CELL ADHESION INHIBITORS BIOGEN INC (US) 2002-12-11 EP claimed
US-6376538-B1 ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES BIOGEN, INC. 2002-04-23 US claimed
US-20060166866-A1 Cell adhesion inhibitors BIOGEN, INC., A MASSACHUSETTS CORPORATION 2006-07-27 US disclosed
US-6630512-B2 Antiinflammatory agents; autoimmune disease BIOGEN, INC. 2003-10-07 US disclosed
US-20030018016-A1 Cell adhesion inhibitors BIOGEN IDEC MA, INC. 2003-01-23 US disclosed
EP-0805796-B1 CELL ADHESION INHIBITORS BIOGEN INC (US) 2002-12-11 EP disclosed
US-6376538-B1 ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES BIOGEN, INC. 2002-04-23 US disclosed
EP-1142867-A2 Cell adhesion inhibitors BIOGEN, INC. (US) 2001-10-10 EP disclosed
EP-0805796-A1 CELL ADHESION INHIBITORS BIOGEN, INC. (US) 1997-11-12 EP disclosed
WO-1996022966-A1 CELL ADHESION INHIBITORS BIOGEN, INC. (US) 1996-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166866-A1 Cell adhesion inhibitors ICAM1, VCAM1, EPCAM MAT2A 2214/4885L3MBTL1 3129/4885MEN1 1437/4885
US-20030018016-A1 Cell adhesion inhibitors ICAM1, VCAM1, EPCAM MAT2A 2214/4885L3MBTL1 3129/4885MEN1 1437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.